pharma news, views and analysis - pharmaphorum.com

Trending

in News
Trial answers the KRAS question for Keytruda in lung cancer
December 13, 2019 Share
X
Trial answers the KRAS question for Keytruda in lung cancer
https://pharmaphorum.com/news/trial-answers-the-kras-question-for-keytruda-in-lung-cancer/
in News
AZ and Daiichi Sankyo’s breast cancer drug delays progression in advanced disease
December 12, 2019 Share
X
AZ and Daiichi Sankyo’s breast cancer drug delays progression in advanced disease
https://pharmaphorum.com/news/az-daiichi-sankyos-breast-cancer-drug-delays-progression-in-advanced-disease/

Latest News

AZ’s Imfinzi approved in early lung cancer in China

AZ’s Imfinzi approved in early lung cancer in China

The Chinese regulator has approved AstraZeneca’s Imfinzi in an early form of lung cancer after treatment with chemotherapy

X

AZ’s Imfinzi approved in early lung cancer in China

https://pharmaphorum.com/news/azs-imfinzi-approved-in-early-lung-cancer-in-china/

BMS preps filings for leukaemia maintenance therapy CC-486

BMS preps filings for leukaemia maintenance therapy CC-486

Celgene’s pipeline has delivered another new drug filing for Bristol-Myers Squibb, thanks to positive results for oral azacitidine

X

BMS preps filings for leukaemia maintenance therapy CC-486

https://pharmaphorum.com/news/bms-preps-filings-for-leukaemia-maintenance-therapy-cc-486/

Gilead to file new CAR-T, setting up potential mid-2020 launch

Gilead to file new CAR-T, setting up potential mid-2020 launch

Gilead’s Kite unit plans to file its latest CAR-T therapy on the basis of a new study showing

X

Gilead to file new CAR-T, setting up potential mid-2020 launch

https://pharmaphorum.com/news/gilead-to-file-new-car-t/

Views & analysis

Pfizer and the UK cancer landscape: the pharmaphorum podcast

Pfizer and the UK cancer landscape: the pharmaphorum podcast

Pfizer’s Dr Olivia Ashman joined me for episode 16 of the pharmaphorum podcast, which focuses on the UK

X

Pfizer and the UK cancer landscape: the pharmaphorum podcast

Q&A: Avacta’s Amrik Basran on immunotherapy

Q&A: Avacta’s Amrik Basran on immunotherapy

Dr Amrik Basran from Avacta explains the current state of cancer immunotherapy and the challenges of moving into

X

Q&A: Avacta’s Amrik Basran on immunotherapy

https://pharmaphorum.com/views-analysis-oncology/avactas-amrik-basran-on-immunotherapy/

Demonstrating the value of RWE

Demonstrating the value of RWE

A new cross-industry effort hopes to research the benefits of RWE and promote acceptance of alternatives to traditional

X

Demonstrating the value of RWE

https://pharmaphorum.com/views-analysis-oncology/demonstrating-the-value-of-rwe/

Debates & Insights

Cost & Management of Oncology Combination Regimens

Cost & Management of Oncology Combination Regimens

Overview Oncology treatment increasingly involves combinations of novel oral and biologic drugs. While combo approaches aren’t new, there

X

Cost & Management of Oncology Combination Regimens

https://pharmaphorum.com/oncology/cost-management-of-oncology-combination-regimens/

Cancer, genomics and personalised medicine: Modelling oncology’s future

Cancer, genomics and personalised medicine: Modelling oncology’s future

Overview The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in

X

Cancer, genomics and personalised medicine: Modelling oncology’s future

https://pharmaphorum.com/oncology/cancer-genomics-and-personalised-medicine-modelling-the-future-of-oncology/

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

11/06/2017

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

A unique example of partnership working across the health system, focusses on the service at large, not just the pill, and uses leading-edge data analytics to analyse, benchmark and visualise the current state of the cancer pathways within the Cancer Vanguard Trusts. Furthermore, it encompasses multiple aspects of the service provision ranging from patient outcomes and experiences, the flow of treatment and the usage of medicine in order to inform an evidence-based and patient-centric approach to service redesign and resource optimisation.

X

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

https://pharmaphorum.com/debates-insight-oncology/improving-outcomes-through-industry-partnership-learnings-from-the-cancer-vanguard/

Partner Content

Attendee List Released for SMi’s 9th Annual RNA Therapeutics

Attendee List Released for SMi’s 9th Annual RNA Therapeutics

RNA Therapeutics

X

Attendee List Released for SMi’s 9th Annual RNA Therapeutics

https://pharmaphorum.com/partner-content-oncology/attendee-list-released-for-smis-9th-annual-rna-therapeutics/

RNA Therapeutics conference will take place in just 4 weeks!

RNA Therapeutics conference will take place in just 4 weeks!

4 Weeks Until RNA Therapeutics

X

RNA Therapeutics conference will take place in just 4 weeks!

https://pharmaphorum.com/partner-content-oncology/rna-therapeutics-conference-will-take-place-in-just-4-weeks/

This Week’s Spotlight Features GSK and Advanced Cell Diagnostics

This Week’s Spotlight Features GSK and Advanced Cell Diagnostics

RNA Therapeutics Feb 2018

X

This Week’s Spotlight Features GSK and Advanced Cell Diagnostics

https://pharmaphorum.com/partner-content-oncology/this-weeks-spotlight-features-gsk-and-advanced-cell-diagnostics/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com